Clinical Trial Update: Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for PerVision, a personalized cancer vaccine for fusion-positive sarcomas, currently recruiting at University Hospital Tübingen,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Rhabdomyosarcoma
• Synovial Sarcoma

Drugs mentioned

• PerVision personalized cancer vaccine

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Ewing Sarcoma, Rhabdomyosarcoma | Phase 1, Phase 2 | Status: RECRUITING